In its first-quarter 2025 investor letter, TimesSquare Capital U.S. Focus Growth Strategy highlighted stocks such as Cencora, Inc. (NYSE:COR). Cencora, Inc. (NYSE:COR) is a pharmaceutical products ...

Shareholders might have noticed that Cencora, Inc. (NYSE:COR) filed its quarterly result this time last week. The early response was not positive, with shares down 3.1% to US$283 in the past week.

U.S. drug distributor Cencora raised its annual profit forecast on Wednesday, driven by robust demand for costly specialty medicines and weight-loss drugs.

Hello, everyone, and thank you for joining the Cencora Fiscal 2025 Second Quarter Results Conference Call. My name is Lucy, and I will be coordinating your call today. [Operator Instructions] I ...

Shares of Cencora Inc. COR slipped 1.63% to $278.38 Monday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX rising 3.26% to 5,844.19 ...

CONSHOHOCKEN, Pa. (AP) — CONSHOHOCKEN, Pa. (AP) — Cencora, Inc. (COR) on Wednesday reported fiscal second-quarter profit of $717.9 million. On a per-share basis, the Conshohocken, Pennsylvania ...

LONDON - Cencora, Inc., a company whose securities are listed on the New York Stock Exchange, has concluded a post-stabilisation period without any stabilisation activities being conducted ...